Last updated: February 25, 2026
What is the Drug Associated with NDC 68968-6637?
NDC 68968-6637 corresponds to Tafasitamab with liso-cel (lisocabtagene maraleucel). This hybrid categorization indicates an approval or combination involving a monoclonal antibody and a CAR-T cell therapy. Specifically, Tafasitamab is an anti-CD19 monoclonal antibody marketed under Monjuvi, primarily approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with other therapies.
Liso-cel (lisocabtagene maraleucel) is a CAR-T cell product used for certain lymphomas, including large B-cell lymphoma. The combination with tafasitamab suggests advanced treatment pathways or high-cost molecular regimens in hematologic oncology.
Market Context and Potential Indications
- Target patient population: Patients with relapsed or refractory DLBCL, with an estimated incidence of approximately 20,000 cases annually in the U.S.
- Competitive landscape: Includes leaders like Roche's Rituxan, Gazyva (obinutuzumab), and other CAR-T therapies such as Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel).
- Regulatory status: As of 2023, tafasitamab is FDA-approved, and combination uses with liso-cel are under clinical or compassionate use pathways, with upcoming approvals potentially broadening the market.
Market Size Analysis
| Parameter |
Data Point |
Source/Notes |
| U.S. DLBCL cases (annual) |
20,000 |
[1] |
| Estimated eligible patients |
70%-80% relapse rate; ~13,000–16,000 patients |
[2] |
| Current treatment market value |
Estimated $2.5 billion (2022) |
[3] |
| CAR-T therapy share |
~50% of relapsed cases |
[4] |
Price Landscape and Projections
-
Tafasitamab (Monjuvi):
Wholesale acquisition cost (WAC): around $10,000 per 10 mg vial. The typical treatment course involves multiple vials over several cycles, leading to approximate total costs in the range of $150,000–$200,000 annually per patient.
-
Liso-cel (Lisocabtagene maraleucel):
Estimated wholesale price for CAR-T cell therapies: $400,000–$475,000 per treatment course, primarily driven by manufacturing complexity, personalization, and logistics.
-
Combination therapy pricing projection:
A combined regimen could escalate costs by 20–30%, reaching roughly $600,000–$800,000 per patient.
Price Trends and Future Projections
| Year |
Price Range per Treatment |
Key Factors Influencing Price |
Source/Notes |
| 2023 |
$600,000 – $800,000 |
Manufacturing input costs, demand |
Based on current CAR-T pricing benchmarks |
| 2025 |
$580,000 – $750,000 |
Competition, biosimilars, value-based models |
Early indications from pricing adjustments in the field |
| 2030 |
$500,000 – $700,000 |
Biosimilar development, health policy changes |
Long-term trend toward cost containment |
Cost-Effectiveness Considerations
Both tafasitamab and liso-cel demonstrate high remission rates. Cost-effectiveness assessments often cite incremental cost-effectiveness ratios (ICERs) between $100,000–$150,000 per quality-adjusted life year (QALY). Payers weigh high upfront costs against improved patient survival and reduced hospitalizations.
Market Dynamics Influencing Price and Adoption
- Reimbursement policies: Payers increasingly favor value-based arrangements.
- Regulatory approvals: Broader indications or combination approvals could expand market size.
- Manufacturing efficiencies: Innovations in cell therapy manufacturing may reduce costs over time.
- Competitive pressure: Entry of biosimilars or new therapies could drive prices downward.
Key Takeaways
- The combined treatment involving NDC 68968-6637 is positioned in a high-cost, high-value segment of hematologic oncology.
- Current prices for similar therapies average between $400,000 and $800,000, with upward or downward adjustments depending on competition and regulatory factors.
- The total market could reach $2 billion within five years, assuming enhanced adoption and expanded indications.
- Cost management strategies, including value-based contracts, will influence pricing pathways.
FAQs
1. Is NDC 68968-6637 associated with a currently approved therapy?
It includes tafasitamab (Monjuvi), approved for DLBCL, and lisocabtagene maraleucel, approved for certain lymphoma types. The specific combination therapy’s regulatory status may vary by jurisdiction.
2. What factors drive the high cost of CAR-T therapies?
Manufacturing complexity, personalization, logistics, and limited scale contribute to elevated prices. High upfront costs are balanced by potential long-term remission.
3. How might pricing evolve in the next five years?
Prices could decrease due to biosimilar entry, manufacturing cost reductions, and policy-driven value-based payment models.
4. Which competitors influence the market for this therapy?
Rituxan, Gazyva, Kymriah, and Yescarta are primary competitors, depending on the indication and combination protocols.
5. What is the potential market size for this combination therapy?
It could target up to 16,000 patients annually in the U.S., with a treated market value reaching approximately $2 billion per year.
References
[1] American Cancer Society. (2022). "Cancer Facts & Figures 2022."
[2] National Cancer Institute. (2021). "Diffuse Large B-Cell Lymphoma."
[3] IQVIA. (2022). "Global Oncology Market Report."
[4] CDC. (2021). "Lymphoma Statistics and Treatment Trends."
